chrisvoncsefalvay/vaers-outcomes huggingface dataset:
developed lymphadenopathy; swelling and pain at right axilla; swelling and pain at right axilla; Neck stiffness as well - still 48 hours post vaccine; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 38 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 01Oct2021 12:30 (Lot number: EW0169) at the age of 38 years as dose 3 (booster) , single for covid-19 immunisation. Relevant medical history included: "Psoriasis, depression, b12 deficiency" (unspecified if ongoing); "Psoriasis, depression, b12 deficiency" (unspecified if ongoing); "Psoriasis, depression, b12 deficiency" (unspecified if ongoing). Concomitant medication(s) included: INFLUENZA, administration date 27Sep2021; ZOLOFT. Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: EL0142, Location of injection: Arm Right, Vaccine Administration Time: 12:00 PM), administration date: 11Jan2021, for Covid-19 immunisation; Bnt162b2 (Dose Number: 1, Batch/Lot No: EK5730, Location of injection: Arm Right, Vaccine Administration Time: 05:30 PM), administration date: 21Dec2020, for Covid-19 immunisation. The following information was reported: LYMPHADENOPATHY (non-serious) with onset 02Oct2021, outcome "not recovered", described as "developed lymphadenopathy"; SWELLING (non-serious), AXILLARY PAIN (non-serious) all with onset 02Oct2021, outcome "not recovered" and all described as "swelling and pain at right axilla"; MUSCULOSKELETAL STIFFNESS (non-serious) with onset 02Oct2021, outcome "not recovered", described as "Neck stiffness as well - still 48 hours post vaccine". Therapeutic measures were taken as a result of lymphadenopathy, swelling, axillary pain, musculoskeletal stiffness.  Additional information: patient received within 2 weeks of vaccination :Zoloft. Prior to vaccination, patient was not diagnosed with COVID-19.  Since the vaccination, patient had not been tested for COVID-19. Device Date and device timestamp was on 04Oct2021. The patient did not reported any allergies.  No follow-up attempts are possible. No further information is expected.
Patient complained of "neck hurts". Neck swelling, jaw and cheek swelling. Low grade fevers ranging between 99.4-99.9 degrees F.
4" redness directly below injection site deep red to purple, warm & tender to touch. Skin peeling away.
pt got shot at 2pm, pt arm started to itch at 2:15pm, pt applied Benadryl cream at 2:20pm, itching started to spread at 3:00pm, 3:00 pt took hydroxyzine, 3:35pm itching not improved, pt applied Benadryl cream to shoulder area at 3:40pm
Patient vaccinated 3/9/2021 with first dose of COVID  vaccine (Pfizer) - next day patient developed body aches, cough, sore throat.  Positive COVID PCR.
Pt complained of arm pain, warmth in area site of injection, fatigue, and problems with motility of arm of injection site
Patient experienced arm soreness 1 day after the vaccine. Six days after the vaccine she noticed lumps on her forearms, neck and stomach. Yesterday she experienced warm and redness on the injection site and still has it today.
On January 21, 2021 at the Clinic, a PA was administering vaccinations during the morning for a four-hour shift, 8 AM to noon. At the end of her shift, she handed off her vaccines to another vaccinator. The PA had three doses of vaccine drawn up at that time, in syringes, on her desk. When the RN inspected the syringes, she found 0.4mL of vaccine had been drawn into those syringes rather than the required 0.3mL. The RN then alerted the lead APRN, who escalated the situation to the manager. The manager then contacted Quality.  The concern was that the PA had been vaccinating patients all morning with an inappropriate dose of vaccine, 0.4mL.  After thorough internal investigation, we found that the PA drew up 38 vaccine doses and administered 35 of them.  Additionally, based on vial usage for the day and total number of vaccines administered, we have concluded that it is highly unlikely that excess vaccine was administered. This was a ?near miss? event and is being reported out of an abundance of caution.
?Moderna COVID-19 Vaccine EUA?  Rash, itching and warmth at and around the injection sight.
Extreme arm pain, cannot even lift arm or lay on it; This is a spontaneous report from a non-contactable other healthcare professional, the patient. A 42-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration on an unknown date in 2021 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included citalopram hydrobromide (CELEXA), naltrexone hydrochloride/ bupropion hydrochloride (CONTRAVE), lisinopril (MANUFACTURER UNKNOWN), vitamin d not otherwise specified (MANUFACTURER UNKNOWN) and vitamin b complex (MANUFACTURER UNKNOWN) and coq12 (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown dates and unknown if ongoing. On 07Mar2021, the patient experienced extreme arm pain that the patient couldn't even lift the arm or lay on it. The event resulted in doctor or other healthcare professional office or clinic visit. No therapeutic measures were taken as a result of the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event extreme arm pain was not recovered at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pt recived first shot of Covid Vaccine at 10:17 around 5 mins after pt started feeling dizzy, Diaphoretic, blurred vision. pt fell from the chair in the observation area, pt was immediately transported to ER .
Patient was given 2 doses of flu vaccine 6 days apart. Error was discovered while entering data. Attempting to reach out to the patient. Outcome unknown.
Two days after Pfizer COVID-19 vaccine at vaccine clinic patient presents to hospital with HA, mild, dry cough, dry throat, and fatigue for three days. SARS-Co-V positive. Managed as an outpatient with OTC medications and improving symptoms on follow-up video visit one week later.
No additional adverse event (AE); ROTATEQ  was administered after temperature excursion; This spontaneous report was received from a medical assistant and refers to an unknown age and gender patient.    The patient's pertinent medical history, concurrent conditions, previous drug reactions or allergies, and concomitant therapies were not reported.  On 14-AUG-2023, the suspect vaccine was exposed to a temperature of 8.9 degree Celsius for a time frame of 12 hours 20 minutes 0 seconds. On 28-AUG-2023, the suspect vaccine was exposed to a temperature of 9.4 degree Celsius  for a time frame 8 hours 20 minutes 0 seconds. No previous temperature excursion occurred.   On 13-SEP-2023, the patient was vaccinated with improperly stored rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral liquid, one dosage form, lot #1968393 was verified to be a valid number, expiration date reported and established as 24-MAY-2024), administered orally for prophylaxis (strength was not provided) (product storage error). No additional adverse event was provided.
Pt's mother describes that the child slept after shots and when the child woke up at 3:05pm, her feet were bright red and then both legs became purplish after 20-30 mins later. Child was screaming for 30 minutes. The child is not cold but warm all over with no seizure and no loss of consciousness.
This spontaneous report as received from a medical assistant refers to a 6 month old female patient. On 05-MAR-2013 the patient was vaccinated with the first dose of LIQUID PEDVAXHIB, lot number reported as (0419AE), expiration date (17-AUG-2014), dose, route of administration and anatomical location were not reported. The medical assistant reported that a patient received a first dose of LIQUID PEDVAXHIB and developed an injection site reaction which was a "small knot" at the injection site. The outcome of injection site reaction was reported as recovered/resolved. This case was reported as the 5th of 5 reports from that office. Additional information has been requested.
Patient inadvertently received undiluted vaccine at roughly 20mcg (double the intended dose). Parents contacted on 7/21/22 and reported 'no side effects'.
The patient reports a headache, nausea and vomiting.; The patient reports a headache, nausea and vomiting.; The patient reports a headache, nausea and vomiting.; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (The patient reports a headache, nausea and vomiting.), NAUSEA (The patient reports a headache, nausea and vomiting.) and VOMITING (The patient reports a headache, nausea and vomiting.) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     The patient's past medical history included Spasmodic dysphonia in August 2021 and Surgery (The patient took some pain and anti nausea medication that she had on hand from a previous surgery.).    On 05-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Nov-2021, the patient experienced HEADACHE (The patient reports a headache, nausea and vomiting.), NAUSEA (The patient reports a headache, nausea and vomiting.) and VOMITING (The patient reports a headache, nausea and vomiting.). At the time of the report, HEADACHE (The patient reports a headache, nausea and vomiting.), NAUSEA (The patient reports a headache, nausea and vomiting.) and VOMITING (The patient reports a headache, nausea and vomiting.) outcome was unknown.            Concomitant medications reported were: shot used for migraine headaches, anti nausea medication and pain medication.  The patient received her first and second dose of Moderna Covid-19 injection on 01-Feb-2021 (lot number 042L20A) and 03-Mar-2021 (lot number 036A21A) respectively.   This case was linked to MOD-2022-512561 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 15-Mar-2022: Non Significant follow up was received: no new information
No additional AE/no PQC.; Physican reported an adult patient received PROQUAD instead of MMRII.; Adult paitent received PROQUAD; This spontaneous report has been received from a physician, regarding an adult patient of unknown age and gender. The patient's pertinent medical history, previous drug reactions or allergies and concomitant medications were not reported.  On an unspecified date in August 2023 (reported as "believes it was today"), the patient was vaccinated with a dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) injection, as prophylaxis (strength, dose, scheme, route and anatomical location of administration were not reported) instead of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (wrong vaccine administered, Product administered to patient of inappropriate age).  No additional event was reported.
fever,, chills, body ache, and foggy mind. started on 15th and continued until the 21st.
Information has been received from a medical assistant referring to a patient of unknown age and gender. The patient's concomitant medication, pertinent medical history and drug reactions/allergies were not reported. On 17-OCT-2018 or 22-OCT-2018 the patient was vaccinated with improperly stored VARIVAX (lot # N029628 and expiration date 23-NOV-2019, route, strength, dose and frequency were not reported) for prophylaxis. Medical assistant also reported the sterile diluent (lot # M041989 and expiration date 03-JUL-2019) used to reconstitute VARIVAX did not undergo a temperature excursion. No adverse effects were reported. The temperature excursion was 6 Fahrenheit to 14 Fahrenheit (also reported as 12 Fahrenheit) for 1 hour and 59 minutes. The previous excursion was 6 Fahrenheit to 14 Fahrenheit for 47 hours and 57 minutes and 15 Fahrenheit to 46 Fahrenheit for 39 hours and 57 minutes. The call was because of a data logger. This is one of three reports from the same reporter.; Sender's Comments: US-009507513-1810USA012248: US-009507513-1810USA010189:
Itchy rash on abd and back noted while in waiting area. Given 37.5 mg PO BENADRYL elixir-rash resolved w/in 30 min. Checked with med control and sent pt home w/mother w/instructions to call pediatrician prior to any more vaccines.
administered with vaccine which was beyond the use date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (administered with vaccine which was beyond the use date) in an 82-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 067F21A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 ml. On 10-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (administered with vaccine which was beyond the use date). On 10-Dec-2021, EXPIRED PRODUCT ADMINISTERED (administered with vaccine which was beyond the use date) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The beyond the use date was reported as 09-Dec-2021 at 10:00PM.  The vial was initially stored in the refrigerator on 28-Nov-2021 in the afternoon and the number of vials were 14.  No concomitant medications were reported.  No treatment information was reported.
Severe headache for 1/12 days. Started getting better second day Extreme nausea the second day  Better the 3rd day
soreness in arm at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (soreness in arm at injection site) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for an unknown indication.     The patient's past medical history included No adverse event.  Concomitant products included HYDROCODONE BITARTRATE, PARACETAMOL (NORCO), IBUPROFEN, ACETYLSALICYLIC ACID (BAYER LOW DOSE), ALPRAZOLAM, LOVASTATIN, AMLODIPINE and TIOTROPIUM BROMIDE (SPIRIVA).    On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021, the patient experienced VACCINATION SITE PAIN (soreness in arm at injection site). At the time of the report, VACCINATION SITE PAIN (soreness in arm at injection site) outcome was unknown.            Treatment information were not provided.
Diarrhea for 24 hrs, followed by shortness of breath and chest pain continuing for weeks.
Swelling around both eyes and hives on face. Reaction was noticed by parent at approximately 11:00 a.m. Patient was administered Children's Benadryl 10ml by mouth and observed in clinic an additional 20  minutes and rechecked by clinic staff prior to leaving office.
After injection of PPSV23 I had redness extending from injection site down to elbow, up to shoulder and around to mid back. Unable to move arm in any direction due to severe pain, swelling. Used ice pack, Bendadryl and Advil. Day two my entire upper arm was still red and a little swollen but I could move it. On the third day the upper arm had turned yellow but the swelling was gone. All symtoms were gone by day five.
Head to toe Rash 10 days later, progressing into raised itchy welts, 101 fever, severe nasal congestion, irritability.
Bump/ball the size of a quarter size not raised; Itchy; Slight soreness; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE MASS (Bump/ball the size of a quarter size not raised), VACCINATION SITE PRURITUS (Itchy) and VACCINATION SITE PAIN (Slight soreness) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     no medical history is provided and concomitant drugs are provided.  Concomitant products included IRON and PANTOPRAZOLE for an unknown indication.    On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Feb-2021, the patient experienced VACCINATION SITE PAIN (Slight soreness). On 09-Feb-2021, the patient experienced VACCINATION SITE MASS (Bump/ball the size of a quarter size not raised) and VACCINATION SITE PRURITUS (Itchy). On 02-Feb-2021, VACCINATION SITE MASS (Bump/ball the size of a quarter size not raised) outcome was unknown, VACCINATION SITE PAIN (Slight soreness) had resolved. At the time of the report, VACCINATION SITE PRURITUS (Itchy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Patient reports itching and circular swollen rash began the day after the injection. Rash persisted and grew - by 8/28/17, rash had become an erythematous ring measuring 6 inches in diameter with a central hematoma where the skin was unraised. Patient was rx Amoxicillin 250mg PO, 1 capsule q8h and Hydroxizine 10mg PO, 1 capsule q8h.
Information has been received from a physician concerning a 12 month old patient who on 5/31/2006 was vaccinated subcutaneously with a 0.5ml dose of measles virus vaccine live  (Enders-Edmonston) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3) (+) varicella Virus Vaccine live (upgrade process) (lot 652234/0951R). On an unspecified date following vaccination, the patient developed a rash. Unspecified medical attention was sought. No outcome was reported. No product quality complaint was involved. Additional information has been requested.
He has had increasing warmth, erythema, and pruritus at all injection sites since yesterday, day of vaccinations.  R thigh - 9.5cm x 12cm area of warmth, erythema, L thigh with 7cm x 4cm area of bright erythema, L deltoid with 3cm x 3cm area erythema.
This spontaneous report as received from a medical assistant (also reported as healthcare worker, C.M.A.) refers to a 18 years old female patient. It was reported that the patient received the second dose of GARDASIL (lot # not reported) in November 2010 and asked if she could be administered the third dose of GARDASIL on 13-SEP-2012. No adverse events were reported. It was unspecified whether the patient sought for medical attention. The outcome was unknown. Additional information has been requested.
Patient was in good health. Got Moderna Covid vaccination. Vague history, but subsequently developed seronegative rheumatoid arthritis (likely days to weeks following).
Client was post vaccination and in the monitored observation area when she developed a migraine headache. She reported her findings to the EMS team and was transferred to a cot in a low lighting, low stimulus area. She had eye covering placed to help with the photo-sensitivity. After approximately 20 minutes her symptoms improved and her sister accompanied her home. The client states that migraines are common for her and she declined further evaluation.
Patient stated he started feeling "funny" approx 1/2 hr after receiving H1N1 vaccine. Stated he felt hot and dizzy. Has had seasonal flu vaccine in past with no problems. Symptoms resolved within 30 mins of onset.
tired; rash with itching; headache; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (tired), RASH PRURITIC (rash with itching) and HEADACHE (headache) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012A21A) for COVID-19 vaccination.     Concurrent medical conditions included Autoimmune disorder (Patient is suffering from auto immune disease and she is on her prescription medication.).    On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, the patient experienced FATIGUE (tired), RASH PRURITIC (rash with itching) and HEADACHE (headache). The patient was treated with PROCHLORPERAZINE EDISYLATE (COMPAZINE [PROCHLORPERAZINE EDISYLATE]) at an unspecified dose and frequency. On 05-Feb-2021, FATIGUE (tired), RASH PRURITIC (rash with itching) and HEADACHE (headache) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  Compazine is used as treatment medication.   This case was linked to MOD-2021-035160 (Patient Link).
Severe Flu symtptoms, exhaustion ,  extreme headache that lasted for at many days (over 1 week)
Even though the post vaccine reactions (fever, body aches, head ache, etc) faded,  there was an uncomfortable feeling in my head/ears, and in both arms.  After a few more days, the aching in both arms (upper muscle, where the shot had been in the one arm, but this was in both arms) faded.  The pressure in my ears continued building, causing intermittent pain.  After two weeks, I called my doctor's office who could not get me in and suggested I go to the care clinic, assuming it was an ear infection.  The care clinic said my ears where clear but it appeared there was swelling and put me on a course of steroids.  Within 4 days, my entire body stopped aching and the swelling was greatly reduced.  The  person on call was a nurse practitioner who said that I was not the first to come in with similar symptoms post booster and that the cause was likely mild (system wide) inflammation since there was no infection present in my ears.  She indicated that the steriods would reduce swelling and inflammation but to follow up with my dr if I did not improve.
Paresthesia over entire body.  Legs felt numb if sitting still/as if they are not attached to body.  Extreme cold in hands and feet.  Redness over all skin.  Head tension and aches.   Started approximately 10 hours after 2nd vaccine injection.  Still lingering into 2nd day.  Have lessened.  Legs still feel numb/not fully attached at times.
Temporary loss of taste a day and a half after receiving the first dose, fever, extreme fatigue, congestion. Tested for Covid-19 on the first day of symptoms and came back negative. Day 5 after the dose and still having congestion. Fever only lasted for one day, on the 27th.
Information has been received from a registered nurse concerning a 22 year old female who on 12-NOV-2007 was vaccinated in the left deltoid with the first dose of Gardasil (lot # 659437/1266U).  On 16-NOV-2007 the patient complained of stiff neck, stiff joints and stiff fingers.  The patient's status was not reported.  Additional information has been requested. This is in follow-up to report(s) previously submitted on 1/7/2008. Information has been received from a registered nurse concerning a 22 year old year old white female weighing 127 pounds and height of 63 inches who at 4:21 PM on 13-NOV-2007 (also reported as 12-NOV-2007) was vaccinated IM in the left deltoid with the first dose of GARDASIL (lot # 659437/1266U). On 16-NOV-2007 the patient complaint of stiff neck, stiff joints and stiff fingers. The patient's status was not reported. Additional information has been requested.
Patient acquired "Park" syndrome; This is spontaneous report from contactable consumer (patient). A patient of an unspecified age and gender received the second dose of BNT162B2 (Pfizer-Biontech Covid-19 Vaccine, Lot Number: EW0162) at single dose, on 15Apr2021, for COVID-19 immunization. Relevant medical history and concomitant medications were unknown. The patient previously on 25Mar2021 received the first dose of BNT162B2 (Pfizer-Biontech Covid-19 Vaccine, Lot Number: ER8727) at single dose, for COVID-19 immunization. On an unspecified date, the patient stated that had been in hospital (12 days). Patient acquired "Park" syndrome (it was not further clarified if consumer meant Parkinson's disease or Parkes syndrome). Patient received blood transfusions. Further clarification was unknown. The patient did not recover from the adverse event at time of this report.  Information on lot/batch number has been requested.